Roivant

Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical holding company that accelerates the development and commercialization of medicines through its distinctive "Vant" model, a network of nimble, focused subsidiary companies such as Immunovant, Priovant, and Pulmovant. Founded in 2014, Roivant advances a pipeline spanning immunology, dermatology, and other therapeutic areas, and has delivered multiple FDA approvals and Phase 3 trial successes. Roivant is a company profile in the API Evangelist network; it operates a corporate and investor web presence but publishes no public developer API surface.

Roivant is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Biopharmaceutical, Pharmaceuticals, and Drug Development.

Roivant’s developer surface includes engineering blog and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub
14.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyHealth TechBiopharmaceuticalPharmaceuticalsDrug DevelopmentLife SciencesImmunology

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 14.3/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/roivant: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Roivant Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 4

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 Investors
Investors

Source (apis.yml)

apis.yml Raw ↑ 
aid: roivant
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/roivant.png
name: Roivant
description: 'Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical holding company that accelerates
  the development and commercialization of medicines through its distinctive "Vant" model, a network of nimble, focused subsidiary
  companies such as Immunovant, Priovant, and Pulmovant. Founded in 2014, Roivant advances a pipeline spanning immunology,
  dermatology, and other therapeutic areas, and has delivered multiple FDA approvals and Phase 3 trial successes. Roivant
  is a company profile in the API Evangelist network; it operates a corporate and investor web presence but publishes no public
  developer API surface.'
url: https://raw.githubusercontent.com/api-evangelist/roivant/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Health Tech
- Biopharmaceutical
- Pharmaceuticals
- Drug Development
- Life Sciences
- Immunology
apis: []
common:
- type: Website
  url: https://roivant.com
- type: About
  url: https://roivant.com/about/company
- type: Blog
  url: https://investor.roivant.com/news-events/press-releases
- type: Investors
  url: https://investor.roivant.com/
- type: PrivacyPolicy
  url: https://roivant.com/privacy-policy
- type: TermsOfService
  url: https://roivant.com/terms-of-use
- type: DomainSecurity
  url: security/roivant-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1